Novel and potential future biomarkers for assessment of the severity and prognosis of chronic heart failure - A clinical review

被引:24
作者
de Virginy, David R. Buvat [1 ]
机构
[1] St Johns Clin, Dept Internal Med, Rolla, MO 65401 USA
关键词
heart failure; biomarkers; prognosis; neurohormones; myocardial remodeling;
D O I
10.1007/s10741-006-0234-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the last two decades, the pathophysiology and biomolecular basis of heart failure syndrome has reached sound and more comprehensive understanding. This knowledge has allowed expert researchers and clinicians to explore an entirely new spectrum of potential biochemical markers derived from different cellular and signaling pathways that lead to myocardial hypertrophy, chronic damage of the myocyte, apoptosis, and, ultimately, myocardial remodeling. Indeed, the link between myocardial remodeling and adverse outcomes, as well as the recognition of the myocardial interstitium as a multifunctional dynamic entity strongly influenced by systemic neurohormonal and inflammatory activation, has provided a solid ground for research of biomarkers that might correlate with severity and prognostication in chronic heart failure. This paper reviews and summarize recent literature on some of the most interesting circulating biomarkers with potential use for the stratification of patients with chronic heart failure.
引用
收藏
页码:333 / 344
页数:12
相关论文
共 128 条
[61]  
LaVecchia L, 1997, AM J CARDIOL, V80, P88
[62]   ELEVATED CIRCULATING LEVELS OF TUMOR-NECROSIS-FACTOR IN SEVERE CHRONIC HEART-FAILURE [J].
LEVINE, B ;
KALMAN, J ;
MAYER, L ;
FILLIT, HM ;
PACKER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (04) :236-241
[63]   EFFECTS OF WARFARIN THERAPY ON PLASMA-FIBRINOGEN, VON-WILLEBRAND-FACTOR, AND FIBRIN D-DIMER IN LEFT-VENTRICULAR DYSFUNCTION SECONDARY TO CORONARY-ARTERY DISEASE WITH AND WITHOUT ANEURYSMS [J].
LIP, GYH ;
LOWE, GDO ;
METCALFE, MJ ;
RUMLEY, A ;
DUNN, FG .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (07) :453-458
[64]   von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? [J].
Lip, GYH ;
Blann, A .
CARDIOVASCULAR RESEARCH, 1997, 34 (02) :255-265
[65]   Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease:: results from the AtheroGene study [J].
Lubos, E ;
Schnabel, R ;
Rupprecht, HJ ;
Bickel, C ;
Messow, CM ;
Prigge, S ;
Cambien, F ;
Tiret, L ;
Münzel, T ;
Blankenberg, S .
EUROPEAN HEART JOURNAL, 2006, 27 (02) :150-156
[66]   Plasma cystatin-C and development of coronary heart disease: The PRIME Study [J].
Luc, G ;
Bard, JM ;
Lesueur, C ;
Arveiler, D ;
Evans, A ;
Amouyel, P ;
Ferrieres, J ;
Juhan-Vague, I ;
Fruchart, JC ;
Ducimetiere, P .
ATHEROSCLEROSIS, 2006, 185 (02) :375-380
[67]   High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure [J].
Maeda, K ;
Tsutamoto, T ;
Wada, A ;
Mabuchi, N ;
Hayashi, M ;
Tsutsui, T ;
Ohnishi, M ;
Sawaki, M ;
Fujii, M ;
Matsumoto, T ;
Kinoshita, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (05) :1587-1593
[68]  
MAJNO G, 1995, AM J PATHOL, V146, P3
[69]   Myocyte apoptosis: Programming ventricular remodeling [J].
Mani, K ;
Kitsis, RN .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (05) :761-764
[70]  
Misson E, 1995, J MOL CELL CARDIOL, V27, pA405